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ABSTRACT 
Aims: to evaluate whether a comprehensive histological evaluation of reticulin fibrosis, collagen 
deposition and osteosclerosis in bone marrow trephine biopsies (BMBs) of primary myelofibrosis (PMF) 
patients may have prognostic implications. 
Methods: reticulin fibrosis, collagen deposition and osteosclerosis were graded from 0 to 3 in a series of 
122 base-line BMBs. Then, we assigned to each case a comprehensive score (RCO score, ranging 
from 0 to 9) that allowed us to distinguish two groups of patients, with low-grade (RCO score 0-4) and 
high-grade (RCO score 5-9) stromal changes. 
Results and discussion: of 122 patients, 88 displayed a low-grade and 34 a high-grade RCO score. The 
latter was more frequently associated with anemia, thrombocytopenia, peripheral blood blasts and 
increased lactate dehydrogenase levels. RCO score resulted strictly correlated with overall mortality 
(p=0.013) and International Prognostic Scoring System (IPSS) risk categories, and was able to 
discriminate the overall survival of both low- and high-grade patients (Log-Rank test: p<0.001). 
Moreover, it proved to be more accurate than the European Consensus on grading of bone marrow 
fibrosis (ECGMF grade) in identifying high-risk patients with poor prognosis. 
A
cc
ep
te
d 
A
rt
ic
le
This article is protected by copyright. All rights reserved. 
Finally, a combined analysis of RCO scores and IPSS risk categories in an integrated clinical-
pathological evaluation was able to increase the positive predictive value (PPV) for mortality in high-risk 
patients. 
Conclusion: the comprehensive RCO score, obtained by histological evaluation of reticulin fibrosis, collagen 
deposition and osteosclerosis, resulted prognostically significant, more accurate than ECGMF grade in 
identifying high-risk patients, and improved PPV when applied in addition to IPSS. 
 
Key words: primary myelofibrosis; bone marrow morphology; reticulin fibrosis; collagen deposition; 
osteosclerosis. 
 
INTRODUCTION 
Reticulin fibers are a physiological component of bone marrow stroma, and can be appreciated as a loose 
meshwork in histological sections stained with silver impregnation. Several reactive and neoplastic conditions 
elicit an increase of the normal meshwork, and an advanced degree of reticulin fibrosis is often accompanied by 
other stromal changes, such as collagen deposition, osteosclerosis and microvessel proliferation. These changes 
are not physiologically found in bone marrow, exception made for sporadic perivascular collagen fibers. The 
pathogenesis of bone marrow stromal changes is unclear, but evidences suggest that reticulin fibrosis and 
collagen deposition may differ in terms of reversibility and clinical implications [1,2]. 
Attempts to estimate the grade of bone marrow fibrosis have been carried out since the first grading system in 
1971 [3]. The 2005 European Consensus on grading of bone marrow fibrosis (ECGMF) [4], included in the 2008 
WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues [5] and confirmed, with minor changes, 
in the 2016 update of WHO classification [6], is the current grading system for bone marrow fibrosis. It focuses 
mainly on reticulin fibrosis, while collagen deposition and osteosclerosis are not evaluated separately, and lack a 
well-established grading system. 
A
cc
ep
te
d 
A
rt
ic
le
This article is protected by copyright. All rights reserved. 
The grade of bone marrow fibrosis according to ECGMF (ECGMF grade) bears clinical implications, especially in 
myeloid neoplasms. It has predictive value on response to therapy and outcome in BCR-ABL1-positive chronic 
myeloid leukemia [7], and correlates with transfusion requirement and prognosis in myelodysplastic syndromes 
[8,9]. Among BCR-ABL1-negative myeloproliferative neoplasms (MPNs), cases of polycythemia vera with 
an initial grade of bone marrow fibrosis (MF-1) show an inferior myelofibrosis-free survival, while advanced 
fibrosis (MF-2 or MF-3) is more frequently associated with a complex karyotype [10,11]. In primary 
myelofibrosis (PMF), the ECGMF grade is associated with relevant hematological findings, and its 
prognostic role is proved in comparison with other prognostic scoring systems [12,13]. Moreover, a more 
accurate stratification of PMF patients is achieved when considering the ECGMF grade along with 
International Prognostic Scoring System (IPSS) risk categories [14]. Patients with a high ECGMF grade 
(MF-2 or MF-3) display features indicative of an advanced disease, such as anemia, leukopenia, 
thrombocytopenia, constitutional symptoms, larger splenomegaly and high IPSS risk categories. They are also 
more likely to have additional somatic mutations in ASXL1 and EZH2 genes, which are connected to adverse 
prognosis, and tend to have a significant reduction of overall survival when compared to early PMF patients [15]. 
Other stromal changes as collagen deposition and osteosclerosis are gaining attention, especially in the 
context of Janus kinase (JAK) inhibitors therapy [16-23] and hematopoietic stem cell transplantation (HSCT) [24]. 
Therefore, a careful histological examination is crucial for PMF patients, both at the first biopsy and during follow-
up. A new grading system of bone marrow stromal changes has been recently proposed by Kvasnicka et al., and 
proved to be reproducible. It evaluates separately reticulin fibrosis, collagen deposition and osteosclerosis, with 
specific recommendations to improve the staining quality and laboratory standards [25]. 
In this study, we hypothesize that a comprehensive assessment of reticulin fibrosis, collagen deposition and 
osteosclerosis may have prognostic implication and allow a better stratification of PMF patients. To verify the 
hypothesis, reticulin fibrosis, collagen deposition and osteosclerosis were first evaluated separately, according to 
the grading system proposed by Kvasnicka et al. [25]. Then, for each case, the evaluated stromal changes were 
summarized in a comprehensive score (RCO score). Finally, the results obtained with RCO score were 
compared to those obtained with ECGMF grade and IPSS risk categories. 
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MATERIALS AND METHODS 
Patients 
The study involved 122 consecutive PMF patients diagnosed between 1998 and 2015 (median follow 
up: 4.7 years, range: 1.4 months - 13.6 years) at the Hematology Division of the Fondazione IRCCS 
Ca’ Granda — Ospedale Maggiore Policlinico of Milan. Inclusion criteria were the trephine biopsy length 
(more than 1 cm) and the availability of complete clinical history, laboratory and follow-up data, and the 
patient’s informed consent. All cases met the 2008 WHO criteria for PMF, and biopsies were performed 
at base-line observation: in particular, no patient received prior cytoreductive therapy. 
The cases were reviewed by two experienced pathologists (UG, SF) and classified, according to the 
2016 updated WHO criteria, as prePMF and overt PMF [6]. 
 
Bone Marrow Evaluation 
Formalin-fixed, paraffin-embedded bone marrow trephine biopsies were cut at a 5-micron interval and the 
resulting sections were stained with Hematoxilin-Eosin, Giemsa, Gomori’s silver impregnation and Masson’s 
trichrome. The grade of bone marrow stromal changes was assessed according to the new grading system [25]. 
We decided not to evaluate microvessel proliferation, another stromal alteration that occurs along with the 
increase of bone marrow fibrosis [26], since it lacks a well-established grading system. 
Perivascular reticulin and collagen fibers were considered as internal quality controls, and fibers density was 
evaluated only in hematopoietic areas. In case of heterogeneous patterns, the final grade was considered the 
highest in at least 30% of bone marrow area. 
Reticulin fibrosis was evaluated on Gomori’s silver impregnation stained slides and scored as: MF-0, scattered 
linear reticulin with no intersections (crossovers), corresponding to normal bone marrow; MF-1, loose network of 
reticulin with many intersections, especially in perivascular areas; MF-2, diffuse and dense increase in reticulin 
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with extensive intersections, occasionally with focal bundles of thick fibers mostly consistent with collagen and/or 
focal osteosclerosis; MF-3, diffuse and dense increase in reticulin with extensive intersections and coarse 
bundles of thick fibers mostly consistent with collagen, usually associated with osteosclerosis. Collagen 
deposition was evaluated on Masson’s trichrome stained slides and scored as: Co-0, perivascular collagen only 
(normal); Co-1, focal paratrabecular and/or central collagen deposition without connecting meshwork; Co-2, 
paratrabecular and/or central deposition of collagen with focally connecting meshwork or generalized 
paratrabecular apposition of collagen; Co-3, diffuse (complete) connecting meshwork of collagen. Osteosclerosis 
was evaluated on Hematoxilin-Eosin stained slides and scored as: Ost-0, regular bone trabeculae (distinct 
paratrabecular borders); Ost-1, focal budding, hooks, spikes or paratrabecular apposition of new bone; Ost-2, 
diffuse paratrabecular new bone formation with thickening of trabeculae, occasionally with focal interconnections; 
Ost-3, extensive interconnecting meshwork of new bone with overall effacement of marrow spaces. Examples of 
the evaluated morphological changes are reported in Figure 1. 
A comprehensive score (RCO – Reticulin, Collagen, Osteosclerosis – score), obtained by summing the grade of 
each morphological parameter (grade of reticulin fibrosis + grade of collagen deposition + grade of 
osteosclerosis), ranging from 0 to 9, was assigned to each case. To simplify clinical applicability, the cases were 
divided into two groups: RCO low-grade (RCO score ranging from 0 to 4) and RCO high-grade (RCO score 
ranging from 5 to 9). We chose to set a cut-off of 5 for RCO high-grade cases because it implied, in our series, at 
least two high-grade (grade 2 or 3) stromal changes. 
 
Statistical Analysis 
Continuous variables were expressed as median and range, and categorical variables as absolute 
frequency and percentage. A logistic model was used to assess association between covariates and 
mortality. Kaplan-Meier survival analysis was used to evaluate different groups of ECGMF grade, RCO 
score and IPSS in relation to time. 
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Statistical significance was set at a level of p <0.05. Sidak correction was used for multiple testing. Given m 
different null hypotheses and a familywise  of 0.05, each null hypothesis with a p-value lower than 1-(1-)1/m 
was rejected. 
Data processing and all the statistical analyses were performed using the SAS software (version 9.2; SAS 
Institute, Cary, NC, USA). 
 
RESULTS 
Base-line characteristics of the patients 
The study involved a consecutive series of 122 PMF patients diagnosed according to the 2008 WHO criteria and 
revised according to the 2016 update of WHO classification; 69 (57%) were revised as prePMF (ECGMF grade: 
MF-0 or MF-1) and 53 (43%) as overt PMF (ECGMF grade: MF-2 or MF-3). 
The series included 56 males and 66 females (M/F = 85%) with a median age at diagnosis of 68 years (range 
30–85). Anemia (hemoglobin <10 g/dL) was found in 20 patients (16%), leukocytosis (leukocytes >25 x109/L) in 4 
patients (3%), and thrombocytopenia (platelets <100 x109/L) in 7 patients (6%). The main clinical data are 
summarized in Table 1. 
JAK2V617F mutation was detected in 81 cases (66%). Among the remaining 41, three carried the MPLW515L 
mutation, one the MPLW515R and 27 a mutation in exon 9 of CALR gene. In the latter group, 15 cases showed 
a type 1 mutation (del52bp), nine a type 2 mutation (ins5bp), and three other variants (del4bp, del19bp and 
del5ins12bp). The remaining 10 patients were “triple-negative” (i.e., with no JAK2, CALR or MPL mutations). 
According to IPSS, 38 cases were stratified as low risk, 51 as intermediate-1 risk, 21 as intermediate-2 risk, and 
12 as high risk. 
By the time of the analysis, 21 patients (17%) had died; leukemic evolution occurred in 14 patients (11.5%), and 
thrombo-hemorrhagic events in 25 (20.5%). 
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Morphological evaluation of Reticulin, Collagen, Osteosclerosis and RCO score 
The histologic analysis of bone marrow stromal changes, according to the grading system proposed by 
Kvasnicka et al. [25], gave the following results: reticulin fibrosis, MF-0=9, MF-1=60, MF-2=31 and MF-3=22; 
collagen deposition, Co-0=64, Co-1=23, Co-2=21 and Co-3=14; osteosclerosis, Ost-0=72, Ost-1=24, Ost-2=19 
and Ost-3=7. Stromal changes evolved harmonically for the three morphological features, with few exceptions. 
Four out of 60 cases with MF-1 reticulin fibrosis displayed Ost-2 osteosclerosis (7%) (Figure 2). Moreover, of 31 
cases with MF-2 reticulin fibrosis, two were associated with a Co-3 collagen deposition and seven with a Ost-2 
osteosclerosis. The details of stromal changes evaluation are listed in Table 2. 
Mortality, as a dependent variable in a logistic model, was associated with the grade of reticulin fibrosis and 
collagen deposition, but not with osteosclerosis. In fact, the risk of death was 3.3 (IC95% 1.3-9.0) folds greater in 
the advanced grade of reticulin fibrosis (grade 2-3 vs 0-1) and 2.7 (IC95% 1.2-6.3) folds greater in the advanced 
grade of collagen deposition (grade 2-3 vs 0-1). 
A comprehensive score (RCO – Reticulin, Collagen, Osteosclerosis – score), obtained by summing the grade of 
each morphological parameter (grade of reticulin fibrosis + grade of collagen deposition + grade of 
osteosclerosis), and thus ranging from 0 to 9, was assigned to each case. 
RCO score 1 was the most frequent in our series: it was found in 51 patients (41.8%), 50 of which showed a MF-
1/Co-0/Ost-0 combination. RCO score 4 was the second most frequent and found in 14 patients (11.4%). It was 
ascribable to a MF-2/Co-1/Ost-1 combination in 11 out of 14 patients (78.5%). 
RCO scores and individual grades of reticulin fibrosis, collagen deposition and osteosclerosis are reported in 
Table 3. 
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Prognostic significance of RCO score 
To simplify the clinical applicability, we divided the patients in two groups, according to their RCO score: RCO 
low-grade (RCO score 0-4) and RCO high-grade (RCO score 5-9). Eighty-eight (72%) out of 122 patients were 
placed in the RCO low-grade group and 34 (28%) in the RCO high-grade group. 
Patients in the RCO high-grade group displayed laboratory features indicative of an advanced disease: they had 
a higher percentage of anemia, thrombocytopenia, leukocytosis, peripheral blood blasts and increased lactate 
dehydrogenase (LDH) levels. 
Clinical features according to RCO grade group are summarized in Table 4. 
RCO score resulted strictly associated (p<0.001) with IPSS risk categories and overall survival (RCO low-grade: 
10 dead out of 88 vs RCO high-grade: 11 dead patients out of 34; p=0.0059). On the contrary, it was not 
associated with the percentage of leukemic transformation (p=0.18) or thrombo-hemorrhagic events (p=0.76). 
RCO score was able to discriminate the overall survival (OS) of patients: the 75th percentile OS in the RCO score 
low-grade group was 12.5 years, against 3.5 years in the RCO score high-grade group (Log-Rank test: p<0.001). 
We compared the OS curves obtained with RCO score to those obtained with ECGMF grade: RCO score turned 
out to be more accurate in identifying high risk patients with poor prognosis (Figure 3A). 
The RCO low-grade group included 11 overt PMF patients (MF-2) with RCO score 4. These patients did not 
seem to differ in terms of OS when compared to prePMF (MF-0 or MF-1) RCO low-grade patients (Figure 3A). 
We compared clinical and pathological features of prePMF and overt PMF patients in the RCO low-grade group. 
As seen in Table 5, no significant difference was found. 
We matched the OS curves obtained with RCO score to those obtained with IPSS risk categories: the two 
systems showed comparable results, even if IPSS was slightly better in differentiating high risk patients after 60 
months of follow-up (Figure 3B). 
Then we investigated if a combined evaluation of RCO score and IPSS risk categories could allow a more 
accurate stratification. For this purpose, each patient was assigned to a further risk subgroup, created by an 
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integrated estimation of IPSS risk categories and RCO score: Low-risk (IPSS low/intermediate-1 risk + RCO low-
grade), Moderate-risk (IPSS intermediate-2/high-risk + RCO low-grade or IPSS low/intermediate-1 risk + RCO 
high-grade), and High-risk (IPSS intermediate-2/high risk + RCO high-grade). RCO score proved to add 
prognostic information to IPSS risk categories: in fact, the combined evaluation was more accurate than IPSS 
alone. For instance, the median survival of intermediate-2/high-risk IPSS patients declined from 9.7 years to 4.9 
years if a high-grade RCO score was associated. A significant difference was also found in OS curves obtained 
with RCO score and IPSS together (p<0.001). These results are summarized in Figure 3C. 
The combined evaluation provided an increase in positive predictive value (PPV) for mortality in the High-risk 
group: PPV raised from 32% (when considering RCO score alone) and 36% (when considering IPSS alone), to 
42% when considering RCO score and IPSS together. The results are listed in Table 6. 
Finally, we compared OS curves resulting from two different combined analyses: IPSS + RCO score vs IPSS + 
ECGMF grade. The former combination was more accurate in discriminating the OS of High-risk patients, 
especially after 60 months of follow-up (Figure 3D). 
 
DISCUSSION 
We hypothesized that a comprehensive histologic evaluation of reticulin fibrosis, collagen deposition and 
osteosclerosis, according to the grading system proposed by Kvasnicka et al. [25] may have prognostic 
implication and may allow a better stratification of PMF patients. 
To verify the hypothesis, we assessed reticulin fibrosis, collagen deposition and osteosclerosis in base-line bone 
marrow trephine biopsies of 122 consecutive PMF patients, assigning a grade from 0 to 3 to each parameter. A 
comprehensive score (RCO score, obtained by summing the individual grade of Reticulin fibrosis, Collagen 
deposition and Osteosclerosis) for each case enabled us to identify two groups of patients characterized by low-
grade (RCO score 0-4) and high-grade (RCO score 5-9) bone marrow stromal changes, and by different clinical 
features. In fact, patients in the RCO high-grade group more frequently displayed laboratory features indicative of 
an advanced disease, such as anemia, thrombocytopenia, peripheral blood blasts and increased LDH levels. 
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RCO score resulted strictly associated with OS and IPSS risk categories. OS curves according to RCO score 
were significantly different for low- and high-grade groups: the 75th percentile value of 12.5 years for RCO low-
grade patients decreased to 3.5 years for RCO high-grade patients. Moreover, RCO score resulted more 
accurate than the current grading system, based on the ECGMF grade, in identifying high risk patients with poor 
prognosis. Interestingly, the subset of RCO low-grade patients with overt PMF (ECGMF grade MF-2) according 
to the 2016 update of WHO classification displayed an OS curve comparable to RCO low-grade patients with 
prePMF (ECGMF grade MF-0 or MF-1), and did not show any significant clinical and pathological differences. 
This finding furtherly supports the value of a comprehensive histologic evaluation of bone marrow stromal 
changes in stratifying PMF patients. 
Finally, a combined assessment of RCO score and IPSS risk categories increased PPV for mortality. In fact, for 
High-risk patients (RCO high-grade and IPSS intermediate-2/high risk), PPV raised from 32% (when considering 
RCO score alone) and 36% (when considering IPSS alone), to 42% when considering RCO score and IPSS 
together. This means that the application of the RCO along with the IPSS risk category allows a better 
stratification of PMF patients. 
To our knowledge, this is the first study that specifically investigates the prognostic significance of a 
comprehensive histologic evaluation of reticulin fibrosis, collagen deposition and osteosclerosis in a series of 
PMF patients. 
The ECGMF grade is known to play a major prognostic role in PMF patients. For example, when our group 
examined the prognostic significance of ECGMF grade in PMF patients and its relationship with IPSS risk 
categories [13,14], the two systems resulted independently able to predict survival at a multivariate analysis. 
Additionally, a more accurate prognostication was achieved when the two systems were used together. More 
recently, a work by Guglielmelli et al. [15] on a large series of PMF patients confirmed our results, disclosing that 
a high ECGMF grade (MF-2 or MF-3) is associated with cytopenias, circulating blasts, larger splenomegaly and a 
higher IPSS risk category. These patients were also enriched in prognostically unfavorable mutations, in 
particular ASXL1 and EZH2. These data suggest that a high ECGMF grade represents an adverse prognostic 
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factor, and that it can provide supplementary information in lower IPSS risk categories, a group of patients where 
clear indications for treatment are still missing. 
Other stromal changes, as collagen deposition and osteosclerosis, remained under-recognized, although 
commonly found in association with advanced bone marrow fibrosis in BCR-ABL1-negative MPNs [27,28]. A 
grading system for reticulin fibrosis, collagen deposition and osteosclerosis was recently proposed by Kvasnicka 
et al. [25]. It proved to be reproducible in a multicenter study that involved 11 haematopathologists in a blinded 
assessment. The overall inter-rater reliability ranged between 0.898 and 0.926 for all three analyzed parameters 
(reticulin fibrosis, collagen deposition and osteosclerosis). An additional issue of that work consists in the 
identification of specific problems and pitfalls in the interpretation of each single morphological parameter (for 
instance, biopsy length, presence of crushing artefacts and squeezing, thickness of sections and quality of 
staining). 
Collagen deposition and osteosclerosis are gaining attention as indicators of therapy response, in the 
background of JAK inhibitors treatment and HSCT. In fact, a stabilization or regression of reticulin fibrosis, 
collagen deposition and osteosclerosis is described after prolonged therapy with JAK inhibitors [18-23]. While a 
prompt reduction in reticulin fibrosis is also reported after HSCT, the complete regression of collagen deposition 
or osteosclerosis is unclear [24]. Hence, a reproducible grading system for collagen deposition and 
osteosclerosis is necessary for a supervision of response to therapy in these patients. 
In conclusion, our study documents that the histologic evaluation of reticulin fibrosis, collagen deposition and 
osteosclerosis in a comprehensive RCO score is prognostically significant, more accurate than ECGMF grade in 
identifying high risk patients with poor prognosis, and improves PPV for mortality when applied in addition to 
IPSS risk categories. Still, two important limitations of our study consist in its retrospective nature and the 
relatively low number of examined patients and clinical events. For this reason, prospective studies with a larger 
number of patients are needed to confirm the prognostic value of the RCO score, to evaluate its relationship with 
the presence of adverse somatic mutations, such as ASXL1 and EZH2, and its relevance in management of PMF 
patients at diagnosis and after therapy. 
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FIGURES LEGEND 
 
Figure 1. Examples of different grades of bone marrow stromal changes: first row, reticulin fibrosis (MF-0, MF-1, 
MF-2, and MF-3; Gomori’s silver impregnation, 20x); second row, collagen deposition (Co-0, Co-1, Co-2, and Co-
3; Masson’s trichrome staining, 20x); third row, osteosclerosis (Ost-0, Ost-1, Ost-2, and Ost-3; Hematoxilin-Eosin 
staining, 20x). 
 
Figure 2. Example of a case with discordant stromal features. A loose interconnecting reticulin meshwork, grade 
MF-1 (A, Gomori's silver impregnation, 20x) was associated with focal paratrabecular collagen fibers, grade Co-1 
(B, Masson's trichrome, 20x) and with a diffuse thickening of bone trabeculae, with hooks, spikes and focal 
interconnections, grade Ost-2 (C, Hematoxilin-eosin, 10x). The case was included in low-grade RCO score group 
(RCO score = 4). 
 
Figure 3A. Overall survival curves of the 122 PMF patients stratified according to the ECGMF grade (grey 
line) vs the RCO score (black line). RCO low-grade (score 0-4) and RCO high-grade (score 5-9). 
 
Figure 3B. Overall survival curves of the 122 PMF patients stratified according to IPSS (grey line) vs RCO 
score (black line). RCO low-grade (score 0-4) and RCO high-grade (score 5-9). 
 
Figure 3C. Overall survival curves of the 122 PMF patients stratified according to IPSS alone (grey lines) vs 
IPSS + RCO (black lines). Low-risk (IPSS low/intermediate-1 risk + RCO low-grade), Moderate-risk 
(IPSS intermediate-2/high risk + RCO low-grade or IPSS low/intermediate-1 risk + RCO high-
grade) and High-risk (IPSS intermediate-2/high risk + RCO high-grade score). 
 
Figure 3D. Overall survival curves of the 122 PMF patients stratified according to the combined evaluation of 
IPSS + ECGMF grade (grey lines) vs IPSS + RCO (black lines). IPSS + ECGMF: Low-risk (IPSS 
low/intermediate-1 risk + ECGMF MF-0/MF-1), Moderate-risk (IPSS low/intermediate-1 risk + 
ECGMF: MF-2/MF-3 or IPSS intermediate-2/high risk + ECGMF MF-0/MF-1) and High-risk (IPSS: 
intermediate-2/high risk + ECGMF MF-2/MF-3). 
IPSS + RCO: Low-risk (IPSS low/intermediate-1 risk + RCO low-grade), Moderate-risk (IPSS 
intermediate-2/high risk + RCO low-grade or IPSS low/intermediate-1 risk + RCO high-grade) and 
High-risk (IPSS intermediate-2/high risk + RCO high-grade).  
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Table 1. Base-line clinical features of the 122 PMF patients according to the 2016 update of WHO classification. 
 prePMF Overt PMF Totals p value (**) 
No. of patients (%) 69 (56.6) 53 (43.4) 122  
Median age at diagnosis, years (range) 66 (30-84) 69 (37-85) 68 (30-85) 0.058 
M/F, ratio 31/38 (0.82) 25/28 (0.89) 56/66 (0.85) 0.805 
Hb level (g/dL), median (range) 13.7 (6.8-17.6) 11.5 (8.1-15.9) 12.8 (6.8-17.6) 0.0001 
Hb level <10 g/dL, no. of patients (%) 5 (7.2) 15 (28.3) 20 (16.3) 0.0018 
PLT count (x109/L), median (range) 726 (54-1695) 424 (38-1685) 681 (38-1695) <0.0001 
PLT count <100 x109/L, no. of patients (%) 1 (1.4) 6 (11.3) 7 (5.7) 0.042 
WBC count (x109/L), median (range) 9 (3.3-22.1) 10.3 (1.9-64.3) 9.5 (1.9-64.3) 0.057 
WBC count >25 x109/L, no. of patients (%) 0 4 (7.5) 4 (3.3) 0.033 
Circulating blasts ≥1%, no. of patients (%) 1 (1.5) 19 (35.8) 20 (16.4) <0.0001 
LDH (IU/l)*, median (range) 441 (172-1293) 853 (174-2640) 518 (172-2640) <0.0001 
No. of deaths (%) 6 (8.7) 15 (28.3) 21 (17.2) 0.005 
No. of leukemic evolutions (%) 5 (7.2) 9 (17.0) 14 (11.5) 0.150 
No. of thrombo-hemorrhagic events (%) 13 (18.8) 12 (22.6) 25 (20.5) 0.655 
JAK2 mutated, no. of patients (%) 
CALR mutated, no. of patients (%) 
   Type 1 mutation 
   Type 2 mutation 
   Other mutations 
MPL mutated, no. of patients (%) 
Triple negative, no. of patients (%) 
51 (73.9) 
13 (18.8) 
6 (8.7) 
5 (7.2) 
2 (2.9) 
1 (1.4) 
4 (5.8) 
30 (56.6) 
14 (26.4) 
  9 (16.9) 
  4 (  7.5) 
  1 (  1.9) 
  3 (  5.7) 
  6 (11.3) 
81 (66.3) 
27 (22.1) 
15 (12.3) 
9 (7.4) 
3 (2.5) 
4 (3.3) 
10 (8.2) 
0.045 
0.045 
 
 
 
0.316 
0.270 
IPSS, no. of patients (%)     
Low risk 31 (44.9) 7 (13.2) 38 (31.1) 
<0.0001 
Intermediate-1 risk 34 (49.3) 17 (32.1) 51 (41.8) 
Intermediate-2 risk 3 (4.3) 18 (34.0) 21 (17.2) 
High risk 1 (1.4) 11 (20.7) 12 (9.8) 
(*) LDH normal values: 135-214 IU/l. 
(**) Given m (=18) different null hypotheses and a familywise  of 0.05, each null hypotheses that has a p-value lower than 1-(1-)1/m (=0.0028) is rejected. 
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Table 2. Details of stromal changes evaluation in 122 PMF patients. 
  Collagen deposition Osteosclerosis 
Reticulin fibrosis Totals Co-0 Co-1 Co-2 Co-3 Ost-0 Ost-1 Ost-2 Ost-3 
MF-0 9 9 0 0 0 8 1 0 0 
MF-1 60 54 6 0 0 56 0 4 0 
MF-2 31 0 17 12 2 8 16 7 0 
MF-3 22 1 0 9 12 0 7 8 7 
Totals 122 64 23 21 14 72 24 19 7 
 
 
 
Table 3. Frequency distribution of RCO scores and percentage of patients with high-grade (grade 2 or 3) reticulin 
fibrosis, collagen deposition and osteosclerosis. 
RCO score 0 1 2 3 4 5 6 7 8 9 
Frequency 8 51 6 9 14 7 8 9 4 6 
MF-2 or MF-3 (%)    55.6 100.0 100.0 100.0 100.0 100.0 100.0 
Co-2 or Co-3 (%)     21.5 71.4 100.0 100.0 100.0 100.0 
Ost-2 or Ost-3 (%)      28.6 50.0 66.7 100.0 100.0 
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Table 4. Base-line clinical features of the 122 PMF patients according to RCO score. 
 RCO score  
 Low-grade High-grade p value (**) 
No. of patients (%) 88 (72.1) 34 (27.9)  
Median age at diagnosis, years (range) 68 (30-85) 69 (37-85) 0.147 
M/F, ratio 38/50 (0.76) 18/16 (1.13) 0.332 
Hb level (g/dL), median (range) 13.3 (6.8-17.6) 10.7 (8.1-15.0) <0.0001 
Hb level <10 g/dL, no. of patients (%) 7 (8.0) 13 (38.2) <0.0001 
PLT count (x109/L), median (range) 715 (54-1695) 303 (38-1129) <0.0001 
PLT count <100 x109/L, no. of patients (%) 1 (1.14) 6 (17.6) 0.0018 
WBC count (x109/L), median (range) 9.4 (3.3-22.1) 10.7 (1.9-64.3) 0.154 
WBC count >25 x109/L, no. of patients (%) 0 (0.0) 4 (11.8) 0.0053 
Circulating blasts ≥1%, no. of patients (%) 3 (3.4) 17 (50.0) <0.0001 
LDH (IU/l)*, median (range) 466 (172-1879) 907 (174-2640) <0.0001 
No. of deaths (%) 10 (11.4) 11 (32.4) 0.0059 
No. of leukemic evolutions (%) 8 (9.1) 6 (17.6) 0.184 
No. of thrombo-hemorrhagic events (%) 21 (23.9) 9 (26.5) 0.764 
JAK2 mutated, no. of patients (%) 61 (69.3) 20 (58.8) 0.271 
IPSS, no. of patients (%)    
Low risk 35 (39.8) 3 (8.8) 
<0.0001 
Intermediate-1 risk 44 (50.0) 7 (20.6) 
Intermediate-2 risk 8 (9.1) 13 (38.2) 
High risk 1 (1.1) 11 (32.4) 
(*) LDH normal values: 135-214 IU/l. 
(**) Given m (=15) different null hypotheses and a familywise  of 0.05, each null hypothesis with a p-value lower than 1-(1-)1/m (=0.0034) 
 is rejected. 
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Table 5. Base-line clinical features of the 88 RCO low-grade patients according to the grade of reticulin fibrosis (ECGMF grade). 
 Low-grade RCO score group  
 MF-0 + MF-1 MF-2 + MF-3 p value (**) 
No. of patients (%) 69 (78) 19 (22)  
Median age at diagnosis, years (range) 68 (35-84) 70 (39-89) 0.2425 
M/F, ratio 31/38 (0.82) 7/12 (0.58) 0.607 
Hb level (g/dL), median (range) 12.8 (6.8-17.6) 13.1 (9.5-15.9) 0.2781 
Hb level <10 g/dL, no. of patients (%) 5 (7) 2 (10) 0.641 
PLT count (x109/L), median (range) 681 (54-1695) 674 (116-1685) 0.3801 
PLT count <100 x109/L, no. of patients (%) 1 (1) 0 (0.0) 1.000 
WBC count (x109/L), median (range) 9.5 (3.3-22.1) 9.4 (5.55-20.7) 0.2798 
WBC count >25 x109/L, no. of patients (%) 0 (0.0) 0 (0.0) 1.000 
Circulating blasts ≥1%, no. of patients (%) 1 (1) 2 (10) 0.116 
LDH (IU/l)*, median (range) 518 (172-1293) 533 (264-1879) 0.0034 
No. of deaths (%) 6 (9) 4 (21) 0.213 
No. of leukemic evolutions (%) 5 (8) 3 (16) 0.362 
No. of thrombo-hemorrhagic events (%) 16 (23) 5 (26) 0.768 
JAK2 mutated, no. of patients (%) 51 (74) 10 (52) 0.095 
IPSS, no. of patients (%)    
Low risk 31 (45) 4 (21) 0.069 
Intermediate-1 risk 34 (49) 10 (53)  
Intermediate-2 risk 3 (4) 5 (26)  
High risk 1 (1) 0 (0.0)  
(*) LDH normal values: 135-214 IU/l. 
(**) Given m (=15) different null hypotheses and a familywise  of 0.05, each null hypothesis with a p-value lower than 1-(1-)1/m (=0.0034) is rejected. 
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Table 6. Absolute mortality (and percentage) in relation to risk subgroups obtained with a combined evaluation of 
IPSS risk categories + RCO score. 
 Dead Alive**  
Risk subgroup* n % n % Total 
Low-risk 8 10.0 71 89.9 79 
Moderate-risk 3 15.8 16 84.2 19 
High-risk 10 41.7 14 58.3 24 
Total 21 17.2 101 82.8 122 
(*) Low-risk (IPSS low/intermediate-1 risk + RCO low-grade), Moderate-risk (IPSS intermediate-2/high risk + RCO low-grade 
or IPSS low/intermediate-1 risk + RCO high-grade) and High-risk (IPSS intermediate-2/high risk + RCO high-grade score). 
(**) Alive or lost at follow-up. 
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